X

During the COVID-19 (Coronavirus) Pandemic: Your doctor may recommend switching you from a biologic to a topical treatment for your plaque psoriasis.1 You should not stop biologic therapy without consulting your doctor.

Reference: 1. American Academy of Dermatology Association. Aad.org. https://www.aad.org/member/practice/coronavirus/clinical-guidance/biologics. Accessed June 5, 2020.

Pay less with the Co-Pay Savings Program*
$0

Eligible commercially insured patients pay as little as $0 per product per prescription.*

*Prescriptions that may be reimbursed under federal or state healthcare programs (including Medicaid and Medicare) are not eligible under this program. Additional restrictions apply.

How it works


1

Download your reusable co-pay card

2

Activate your card by visiting:
activatethecard.com/7378/

3

Present this card to your pharmacist

Example of ULTRAVATE Lotion copay card
DOWNLOAD THE CO-PAY CARD
VIEW FAQS
INDICATIONS AND USAGE

ULTRAVATE (halobetasol propionate) Lotion is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Effects on Endocrine System: Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression may occur, with the potential for glucocorticosteroid insufficiency during or after treatment. Systemic effects of topical corticosteroids may also include Cushing’s syndrome, hyperglycemia, and glucosuria. Systemic absorption may require evaluation for HPA axis suppression. Use of potent corticosteroids on large areas, for prolonged durations, under occlusive dressings, or on an altered skin barrier may increase systemic exposure. Children may be more susceptible to systemic toxicity when treated with topical steroids.

Local Adverse Reactions: Local adverse reactions with topical steroids may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection and miliaria. These may be more likely to occur with occlusive use, prolonged use or more potent corticosteroids, including ULTRAVATE.

Concomitant Skin Infections: Use an appropriate antimicrobial agent if a skin infection is present or develops.

Allergic Contact Dermatitis: Discontinue ULTRAVATE Lotion if allergic contact dermatitis is established.
In clinical trials the most common adverse reactions (≥1%) were telangiectasia, application site atrophy, and headache.

Please see the Full Prescribing Information for complete prescribing details.